Intas' biosimilar Enbrel debuts at hefty discount in India
This article was originally published in Scrip
Executive Summary
Intas Pharmaceuticals has launched its cut-price etanercept, a biosimilar version of Amgen's TNF-inhibitor Enbrel, on the Indian market.
You may also be interested in...
Intas' MD On Acquiring Best-Performing Assets And Brexit
India's largest privately held pharmaceutical company, Intas, says that it understands Europe well and that the best-performing assets acquired from Teva there are a "perfect fit" for its business. Intas vice chair and managing director Binish Chudgar spoke to Scrip on the buyout and why Brexit isn't a major concern - at least for now.
Indian Avastin Versions Head For Debut; Watch Off-Label Space
Cut-price versions of Roche's anticancer, Avastin (bevacizumab), may well be on their way to the Indian market after a key local expert panel recently recommended the biosimilars for marketing. And "improvements" to facilitate off-label use of the product also appear to be on the agenda of some biosimilar players.
Indian Avastin Versions Head For Debut; Watch Off-Label Space
Cut-price versions of Roche's anticancer, Avastin (bevacizumab), may well be on their way to the Indian market after a key local expert panel recently recommended the biosimilars for marketing. And "improvements" to facilitate off-label use of the product also appear to be on the agenda of some biosimilar players.